Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGLL | Q99685 | 3/20 | 0.46 |
| ▸ | ENPP2 | Q13822 | 3/20 | 0.42 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | PARP1 | P09874 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15041959 | 0.89 | MET (0.44) | PARP1 | |
| SCHEMBL15041960 | 0.89 | HPGD (0.45) | PARP1 | |
| SCHEMBL15023448 | 0.88 | PARP1 (0.36) | POLBPARP1 | |
| SCHEMBL15022485 | 0.85 | PARP1 (0.44) | POLBPARP1 | |
| SCHEMBL15022973 | 0.85 | MAPT (0.48) | PARP1 | |
| SCHEMBL13465593 | 0.80 | PARP1 (0.51) | PARP1 | |
| SCHEMBL12516591 | 0.79 | HPGD (0.43) | PARP1 | |
| SCHEMBL13449418 | 0.78 | PARP1 (0.41) | PARP1 | |
| SCHEMBL13275245 | 0.78 | PARP1 (0.41) | MGLLPARP1 | |
| SCHEMBL13449274 | 0.78 | PARP1 (0.41) | PARP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130158041-A1 | Tyrosine Kinase Inhibitors | MERCK SHARP & DOHME CORP. | 2013-06-20 | — | — | US | disclosed |
| US-20130158041-A1 | Tyrosine Kinase Inhibitors | MERCK SHARP & DOHME CORP. | 2013-06-20 | — | — | US | disclosed |
| WO-2012030633-A1 | TYROSINE KINASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2012-03-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130158041-A1 | Tyrosine Kinase Inhibitors | MET, ABL1, ERBB2 | MGLL 3999/4885ENPP2 1182/4885PTGDR2 2392/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.